Work activity and phenylalanine levels in a population of young adults with classic PKU

Similar documents
Nutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria

Chapter 1: What is PKU?

Molecular Genetics and Metabolism

Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age

Not intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age

2015 PKU Patient Survey Results. National PKU Alliance PO Box 501, Tomahawk, WI

Research Article The Association between EEG Abnormality and Behavioral Disorder: Developmental Delay in Phenylketonuria

Original Articles. Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG

Committee Approval Date: August 15, 2014 Next Review Date: September 2015

ESPEN Congress Madrid 2018

INVESTIGATION THE PREVALENCE OF MUTATIONS IVS 10 AND R158Q IN A NUMBER OF IRANIAN PATIENTS WITH PKU

The neonatal tetrahydrobiopterin loading test in phenylketonuria: what is the predictive value?

Genetic Counselors role in maternal PKU: Patient and Genetic Counselor perspectives. Master s Thesis. Presented to

Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

NEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR

Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line

Disclosure. I have no disclosures to mention

1 Cognitive, Psychological and Behavioral Assessment Based Evidence

PKU, KUVAN, and You PKU treatment and support for adults and young adults

PKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP

Risk of infectious mononucleosis among agonistic swimmers: a cross-sectional study

Clinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: P

Suboptimal provision of medications and dietary products for phenylketonuria in Malta

TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group

Phenylketonuria: Optimizing Therapeutic Efficacy

NIH Public Access Author Manuscript Curr Dir Psychol Sci. Author manuscript; available in PMC 2010 February 1.

PKU, a genetic disease, illustrating the principle:

Screening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force

Phenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine

Emiliano Chisci. Chirurgia Vascolare USL Toscana Centro San Giovanni di Dio - Firenze

C.I. di Metodologia clinica

EARLY TREATMENT OF PHENYLKETONURIA AND DEVELOPMENTAL ABILITIES

NOAC in the Real World

University of Groningen

CLINICAL NUTRITION. Body mass index in adult patients with diet-treated phenylketonuria

Summary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism

Adult PKU. Important Information for You. Mead Johnson Metabolics

PHENYLKETONURIA. Debbie Galo

BAHAN AJAR IV Phenylketonurias (Phenylalanine Hydroxylase Deficiency) Nama Mata Kuliah/Bobot SKS : Sistem Neuropsikiatri / 8 SKS

Relationship between socioeconomic status and quality of life of children with phenylketonuria

ARTICLE. The Magnitude and Challenge of False-Positive Newborn Screening Test Results. hereditary metabolic diseases

Amal Alamri. Phenylketonuria

Il trattamento endovascolare dell aorta sottorenale (EVAR) mediante anidride carbonica (AI-CO 2 )

Emorragie e trombosi in corso di trattamento anticoagulante. Francesco Marongiu. University of Cagliari, Cagliari, Italy

PKU PKU. Phenylketonuria TEMPLE. Information for families following Information for families after a positive newborn screening

Annual Conference. 34th. The Rendezvous Hotel Skipton, Yorkshire. Welcome to. Programme Information & Abstracts

Prerequisites Amino acid synthesis and degradation pathways. Integration of amino acid metabolic pathways with carbohydrate metabolic pathways.

SCUOLA DI SPECIALIZZAZIONE IN FISICA MEDICA. Sistemi di Elaborazione dell Informazione. Introduzione. Ruggero Donida Labati

Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study

A. We are constantly being tested (from birth). 1) Why? Test newborns to check for congenital health problems. 2) What does congenital mean?

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and

Sapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four

Ipogonadismo e carcinoma prostatico quando si può trattare con testosterone?

Phenylketonuria Jonathan Baghdadi and Evan Marlin

Panel: Report of Scientific Advisory Board Research Advancements July 30, 8:15am-9:15am

Molecular Genetics and Metabolism

Table of Contents Preface...1 What is PKU?...2 Where does PKU come from?...3 How is PKU Treated?...4 Controlling Blood Phe *...5 Phenyl-Free How

Boston Children s Hospital Transition Toolkit

PAH phenylalanine + oxidant tyrosine CH 2 +H 3 N

An introduction to Phenylketonuria (PKU)

4. FJ van Spronsen, GM Enns. Future treatment strategies in phenylketonuria. Molecular Genetics and Metabolism 99 (2010): S90 S95.

Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy

Phenylalanine. in cases of hyperphenylalaninemia and tetrahydrobiopterin deficiency

Does a single plasma phenylalanine predict quality of control in phenylketonuria?

PKU (Phenylketonuria) Serum HPLC Analysis Kit User Manual

Firenze, 21/07/2017. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia Università Federico II Naples, Italy

Indication criteria for disease: Phenylketonuria (PKU) [PAH]

Clinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy. December Reference : NHSCB/E6/a

Phenylketonuria Treatment s Impact on Physical Growth: A Spanish Retrospective Longitudinal Study

Food and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran b

Osteoarthritis is one of the main causes

- Aya Alomoush. - Talal Al-Zabin. - Belal Azab. 1 P a g e

Supplementary appendix

New Drug Evaluation: Pegvaliase-pqpz injection, subcutaneous

DISORDERS TOWARD EUROPEAN GUIDELINES FOR PKU: HOW TO SPEAK A COMMON LANGUAGE?

Phenylketonuria in Iranian population: a study in institutions for mentally retarded in Isfahan

Senior Vice President, Medical Affairs and Health Outcomes, 150 South Saunders Road, Lake Forest, IL 60045, Horizon Pharma USA, Inc, USA

Two Siblings of Hyperphenylalaninemia: Suggestion to a Genetic Variant of Phenylketonuria

First Issued: 6/29/2007 Revisions: 12/10/2008, 5/12/2010

IL MANAGEMENT DEL DOLORE CRONICO NEL PAZIENTE ANZIANO Malattie, dolore cronico e sofferenza del paziente anziano

DRG 183 AND 184: ANALYSIS ON THE APPROPRIATNESS OF HOSPITAL ADMISSIONS ACCORDING TO PROTOCOL PRUO. A LOCAL EXPERIENCE

Subject: Pegvaliase-pqpz (Palynziq )

mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE

Mutational and phenotypical spectrum of phenylalanine hydroxylase deficiency in Denmark

Neurocognitive and Behavioral Issues in PKU

Ambiente e salute globale: medicina di genere

Castelfranco Veneto. La prevenzione primaria dell ictus

Emotional Outcome of Adolescents and Young Adults With Early and Continuously Treated Phenylketonuria

The National Society for Phenylketonuria (United Kingdom) Ltd. The Child with PKU. Brenda Clark Professor Forester Cockburn Dr Linda Tyfield

PKU, KUVAN, and Your Child Making smart choices for PKU treatment

Phenylalanine hydroxylase (PAH)

CURRICULUM VITAE ET STUDIORUM

7 Medical Genetics. Hemoglobinopathies. Hemoglobinopathies. Protein and Gene Structure. and Biochemical Genetics

The Effect of Phenylalanine Test Frequency on Management of Phenylketonuria (PKU)

Phenylketonuria patients and their parents knowledge and attitudes to the daily diet - multi-centre study

LA CHEMIOTERAPIA DI I LINEA

Long-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study. abstract ARTICLE

Cranial Ultrasonography in Maple Syrup Urine Disease

Transcription:

118 Med Lav 2017; 108, 2: 118-122 DOI: 10.23749/mdl.v108i2.5984 Work activity and phenylalanine levels in a population of young adults with classic PKU Michele Augusto Riva 1, Fabiana Madotto 1, Massimo Turato 1, Elisabetta Salvatici 2, Silvia Indovina 1, Marcello Giovannini 3, Enrica Riva 3, Giancarlo Cesana 1 1 Research Centre on Public Health, School of Medicine and Surgery, University of Milano Bicocca, Monza, Italy 2 Department of Pediatrics, San Paolo and San Carlo Hospital, Milan, Italy 3 Department of Health Sciences, University of Milan, Milan, Italy Key words: Phenylketonuria; phenylalanine; rare disease; occupational medicine Parole chiave: Fenilchetonuria; fenilalanina; malattia rara; medicina del lavoro Summary Background: Phenylketonuria (PKU) is an inborn error of metabolism characterized by increased blood concentrations of phenylalanine (Phe). Objectives: The aim of the present study was to assess the association between the metabolic compliance of adult patients affected by classic PKU and the characteristics of their present and past occupations. Methods: The study population consisted of working adults, affected by classic PKU, and following a dietary treatment. Univariate linear-mixed models and multivariate analysis were applied to assess the association between Phe blood levels and individual covariates: age, sex, time at diagnosis, educational level and work characteristics. Results: A linear relationship was found with age (an average annual increase of 30.56 µmol/l (C.I. 95%: 7.53; 53.60) in the mean Phe blood levels). Full-time work appeared to be associated with a worse metabolic compliance when compared to part-time work (mean Phe blood levels >281.11 µmol/l). Shift work was related to a worse metabolic compliance, with mean Phe plasmatic levels >356.73 µmol/l. Conclusions: Our data suggests that work may influence the metabolic compliance in adults with PKU. In particular, a part-time employment could allow for a better metabolic compliance, while daily work should be preferred to shift work. Riassunto «Attività lavorativa e livelli di fenilalanina in una popolazione di giovani adulti affetti da PKU classica». Introduzione: La fenilchetonuria (PKU) è un errore congenito del metabolismo caratterizzato da elevate concentrazioni di fenilalanina (Phe) nel sangue. Obiettivi: Lo scopo del presente studio è valutare l associazione tra la compliance metabolica di una popolazione di adulti affetti da PKU classica e le caratteristiche delle loro attività lavorative presenti e passate. Metodi: La popolazione era composta da lavoratori adulti affetti da PKU classica in trattamento dietetico. Sono state effettuate analisi univariate e multivariate per valutare l associazione tra le concentrazioni ematiche di Phe e le covariate individuali: età, sesso, età alla diagnosi, livello di istruzione, e caratteristiche del lavoro. Risultati: Si è individuata una relazione lineare con l età, con un incremento annuo medio di 30,56 µmol/l (I.C.95%: 7,53; 53,60) nei livelli ematici medi di Phe. L attività a tempo pieno sembra essere associata Pervenuto il 26.11.2016 - Revisione pervenuta il 21.2.2017 - Accettato il 14.3.2017 Corrispondenza: Michele Augusto Riva, M.D., Ph.D., Centro di Studio e Ricerca sulla Sanità Pubblica (CeSP), Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano Bicocca, via Cadore 48, 20900 Monza, Italy. Tel. +39 039 2333098 - Fax +39 02 64488169 - E-mail: michele.riva@unimib.it open access www.lamedicinadellavoro.it

work activity in a population of pku patients 119 a una peggiore compliance metabolica quando confrontata con l attività part-time (livelli ematici medi di Phe più elevati di 281,11 µmol/l). Il lavoro a turni è risultato correlato a una compliance metabolica peggiore, con livelli ematici medi di Phe più alti di 356,73 µmol/l. Conclusioni: I nostri dati suggeriscono che l attività lavorativa potrebbe essere in grado di influenzare la compliance metabolica in adulti con PKU. In particolare, un lavoro parttime potrebbe consentire una migliore compliance metabolica, mentre un lavoro a giornata dovrebbe essere preferito ad un lavoro a turni. Abbreviations: PAH: phenylalanine hydroxylase; Phe: phenylalanine; PKU: Phenylketonuria Introduction Phenylketonuria (PKU) is an inborn error of metabolism due to autosomal recessive mutations in the gene coding for phenylalanine hydroxylase (PAH), an enzyme that metabolizes the amino acid phenylalanine (Phe) to tyrosine. The increased blood concentrations of Phe (hyperphenylalaninemia) have serious pathological consequences: severe mental retardation and a variety of additional symptoms, which may include motor deficits, seizures, eczematous rash, hypopigmentation of skin and hair, aberrant behaviour and psychiatric symptoms (2). Nowadays, mass screening programmes and the introduction of a Phe-restricted diet in the first weeks after birth, can prevent hyperphenylalaninemia and the consequent mental retardation, allowing the patients to live a normal life. Although early detection and treatment are essential to improve the psychosocial outcome of the patients, early- and well-treated patients may also show some neurological and psychiatric symptoms (3, 4). These patients may also experience what are commonly referred to as hidden disabilities, including mild impairment of executive functions, reduced processing speed, social difficulties, and emotional problems that may remain unnoticed for years (6). Several studies have associated these manifestations of PKU in adult patients to their Phe blood levels (6, 9), addressing the importance of the maintenance of a good metabolic control throughout life. The nutritional management of PKU is complex, costly and highly time-consuming, requiring knowledge of food composition, and continuous food measurement (3, 5, 9). Given its complexity, different social aspects including work may influence the adherence to the dietary treatment and metabolic compliance (1). In the present study, we aimed at correlating the Phe level in a population of adult patients affected by classic PKU with their present and past occupations. Methods Study design and patient enrolment We enrolled PKU patients attending a specialist outpatient clinic. The inclusion criteria were adult age (18 years old or older), diagnosis of classic PKU (blood Phe: >1200 µmol/l), and availability of monthly data in the period from 2006 to 2014 regarding their blood Phe levels, dietary treatment, and occupational status. We selected only those patients who had worked for at least one month during the follow-up period. Subjects might have changed their occupational status during this time. In detail, we considered age, sex, time at diagnosis (neonatal or >4 weeks after birth), educational level (primary, lower secondary school, upper secondary school, and higher education), employment status (employment and unemployment), type of contract (regular and irregular) and work characteristics (full-time employment, part-time employment, daily work, shift work). The last three covariates were evaluated monthly during the follow-up period. Statistical analysis Results were reported as frequency for discrete variables, and as mean values (± standard deviation) for continuous variables. Differences between proportions were tested with Fisher s exact test. We applied univariate linear-mixed models to assess the

120 riva et al association between concentrations of Phe in the blood and individual covariates. With a multivariate analysis, we evaluated the combined effects of the covariates that resulted significantly associated with a variation of Phe blood levels in the univariate analysis. For all statistical tests, a pre-specified twosided α of 0.05 was regarded as statistically significant. All analyses were performed using SAS software, version 9.2 (SAS Institute, Cary, NC, USA). Results The study population consisted in 20 adult subjects affected by classic PKU. At baseline, the mean age of the study population was 32.55 (±7.37) years; 35.0% were men and most of the patients had primary (50.0%) and lower secondary school (40.0%) educational level. Half of the patients worked for at least 87.32 (62.15-89.16) months during the followup period. Thirteen subjects (65.0%) had an early diagnosis because of new-born screening programmes. The median number of Phe measurements was 46 (36-76), and the mean Phe levels in the population was 582.61 (±251.96) µmol/l (table 1). In the univariate model (table 2), no significant difference in Phe blood levels was observed in relation to sex, educational levels and time at diagnosis. A linear relation was found with age, with an average annual increase of 30.56 µmol/l (95% confidence interval (CI): 7.53; 53.60) in the mean Phe blood levels. Full-time employment appeared to be associated with a worse metabolic compliance when compared to part-time employment, with mean Phe blood levels >281.11 µmol/l (95% CI: 159.63; 402.59). Table 2 shows a significant difference for Table 1. Main characteristics of study population Patients, n 20 Baseline - Demographic characteristics Sex, n (%) Men 7 (35.0) Women 13 (65.0) Age, years Mean (SD) 32.55 (7.37) Median (IQR) 31.50 (37.00-38.50) Time at diagnosis, n (%) Neonatal screening 13 (65.00) After 4 week from born 7 (35.00) Educational level, n (%) Primary school 10 (50.00) Lower secondary school 8 (40.00) Upper secondary school 2 (10.00) Higher education 0 (0.00) Follow-up Clinical characteristics Follow-up period, months Median (IQR) 88.31 (84.85-89.34) Period of employment during follow-up, months Median (IQR) 87.32 (62.15-89.16) Number of Phe measurements for each patients during follow-up Median (IQR) 46 (36-76) Phe (µmol/l) average value Mean (SD) 582.61 (251.96) Abbreviation: SD: Standard Deviation; IQR: Interquartile Range

work activity in a population of pku patients 121 Table 2. Linear-mixed models to assess the association between Phe values and covariates Beta 95% CI p-value N Univariate model Age 30.56 7.53 ; 53.60 0.0093* 1,230 Sex (reference category: Man) 1,230 Woman 127.76-109.79 ; 365.31 0.2918 Time at diagnosis (reference category: Neonatal screening) 1,230 After 4 weeks -75.64-307.95 ; 156.67 0.5234 Education (reference category: Upper Secondary School) 1,230 Primary School 81.41-97.07 ; 259.89 0.3713 Lower Secondary School 24.81-158.52 ; 208.14 0.7908 Employment Status (reference category: Employed) 807 Unemployed -61.96-225.56 ; 101.65 0.4579 Type of contract (reference category: Regular) 803 Irregular 227.87 8.81 ; 446.93 0.0415* NA -35.58-234.65 ; 163.48 0.7261 Work Characteristics (reference category: Full-time employment) 803 Shift work 356.73 242.58 ; 470.87 <.0001* Part-time employment -281.11-402.59 ; 159.63 <.0001* NA -87.17-279.78 ; 105.45 0.3751 Multivariate model 803 Age 23.34 2.13 ; 44.55 0.0310* Work Characteristics (reference category: Full-time employment) Shift work 450.12 338.41 ; 561.82 <.0001* Part-time employment -208.69-334.67 ; -82.70 0.0012* NA -96.54-267.21 ; 74.13 0.2676 Abbreviations: CI: confidence interval; N: number of observations used in the linear-mixed models; NA: not applicable (periods when patients did not work) *Statistically significant at the level 0.05 irregular vs. regular type of contract. In addition, shift work was related to a worse metabolic compliance, with mean Phe blood levels >356.73 µmol/l (95% CI: 242.58; 470.87). Finally, we associated the covariates age and work characteristics (full-time employment, part-time employment, shift work) to the Phe blood levels in the multivariate analysis (table 2). Adjusting for the other variables in the model, age still showed a linear relationship with Phe blood levels, with an average annual increase of 23.34 µmol/l (95% CI: 2.13; 44.55). Shift work and part-time employment seemed to be related respectively to an increase and a decrease of the average Phe blood levels. Conclusions To the best of our knowledge, this is the first study to investigate the potential effects of work activity on Phe levels in PKU, one of the most common amino acid metabolism disorders. PKU is a rare disease and, as a consequence, the number of subjects enrolled in this study was low, but the high number of Phe measurements available for each subject and the long follow-up period allowed us to investigate the relationship between Phe levels and work activity. We did not find any difference in Phe blood levels when the subjects were unemployed as op-

122 riva et al posed to when they were employed. In particular, the influence of employment status on Phe blood levels may not be satisfactorily investigated in our study because of the short periods of inactivity of each subject. Some characteristics of work seem to influence the Phe blood levels of workers with classic PKU. A part-time employment seems to be related to a better compliance as opposed to a fulltime employment. In relation to the work schedule, a worse compliance seems to be found in shift work. A possible explanation of our findings lies in the increased difficulties that certain aspects of the work schedule may put in following an already complex strict dietary scheme. It is not always feasible for workers, for example, to have a lunch break at home or to prepare their meals in advance and to consume them at the workplace. Nor it is recommended, in order to maintain constantly low Phe blood concentrations throughout the day, to have a free daily meal and compensate for it with a more Phe restricted diet in the remaining meals of the day. The amino acidic component of the diet importantly affects the stability of Phe blood levels, and should be spread evenly in three to four doses throughout the day (7). Due to the aforementioned hidden disabilities, such as a reduced processing speed, a poor metabolic compliance may have an influence on working performance, increasing the likelihood of operative errors and work-related injuries that may also involve third parties. For this reason, employers should guarantee these workers to follow adequately their dietary treatment during working time for a better metabolic control. In this regard, the possibility to have a personalised menu in agreed restaurants near the workplace or at the company s canteen could be of extreme help. Furthermore, at least one break apart from lunch break should be allowed, to consume protein substitutes that can help in achieving stable Phe concentrations. Finally, the findings in the present study that should be confirmed on a larger population of PKU workers and be implemented on the aspects concerning the effects of PKU on work activity could also be of help for occupational health physicians in evaluating the occupational clearance of PKU workers: a part-time employment could allow for a better metabolic compliance. Daily work should be generally preferred to a shift work. No potential conflict of interest relevant to this article was reported References 1. Bik-Multanowski M, Didycz B, Mozrzymas R, et al: Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis 2008; 265: 630-633 2. Blau N, van Spronsen FJ, Levy HL: Phenylketonuria. Lancet 2010; 376: 1417-1427 3. Burton BK, Leviton L: Reaching out to the lost generation of adults with early treated phenylketonuria (PKU). Mol Genet Metab 2010; 101: 146-148 4. Demirkol M, Giżewska M, Giovannini M, Walter J: Follow up of phenylketonuria patients. Mol Genet Metab 2011; 104 (Suppl): S31-S39 5. Eijgelshoven I, Demirdas S, Smith TA, et al: The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands. Mol Genet Metab 2013; 109: 237-242 6. Gentile JK, Ten Hoedt AE, Bosch AM: Psychosocial aspects of PKU: hidden disabilities - a review. Mol Genet Metab 2010; 99: S64 S67 7. MacDonald A, Rylance G, Hall SK, et al: Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child 1996; 74: 412-417 8. Scriver CR, Kaufman S, Eisensmith E, Woo SLC: The hyperphenylalaninemias. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. 7th edition. New York: McGraw-Hill; 1995: 1015-1075 9. van Spronsen FJ, Burgard P: The truth of treating patients with phenylketonuria after childhood: The need for a new guideline. J Inherit Metab Dis 2008; 31: 673-679